Lei-Lei Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lei-Lei Ma has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Fei-Juan Kong
Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Junbo Ge
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases
3 shared publications Cheng Wu
Department of Anesthesiology and Pain Medicine, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China
2 shared publicationsJian-Bing Zhu
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
2 shared publicationsJian-Ping Wu
Department of Anesthesiology and Pain Medicine, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China
2 shared publications- Jianbing Zhu
Department of Cardiology, The First Affiliated Hospital of Nanchang University, Nanchang, China
2 shared publications
Latest Publications
- 6 February 2025
- Published by IOP Publishing in Medical Engineering & Physics
- Vol. 142 (1) , 104374
A coronary atherectomy system with a novel burr design for two-phase operation
A coronary atherectomy system (CAS) was developed with a novel burr designed for a two-phase atherectomy procedure: low-speed drilling for lesion crossing and high-speed orbiting to achieve luminal gain, to removal the stenosis in artery. To investigate the CAS mechanism and validate its efficacy and safety. Engineering bench-top testings were conducted to evaluate the burr crossing time, luminal gain, debris size, temperature rise, and grinding force together with in-vivo and ex-vivo swine studies. The bench-top engineering testing results showed that the CAS can expand the calcified lumen diameter from 0.4 to 1.7 mm and the debris size, temperature rise, and grinding force were relatively low and safe. In the in-vivo swine study, the media and internal elastic membrane remained intact. The intima of the artery was removed at the 0-day follow-up and re-growthed at the 30-day follow-up. No abnormal phenomenon in the digital subtraction angiography, blood testing, ECG, and anatomy analysis were found. The ex-vivo study, by inserting a plaque surragate (graphite) into the coronary artery, showed similar efficacy in luminal gain and safety. This study demonstrated the efficacy and safety of CAS device with the novel two-phase burr design.
- 6 February 2025
- Published by IOP Publishing in Medical Engineering & Physics
- Vol. 142 (1) , 104374
A coronary atherectomy system with a novel burr design for two-phase operation
A coronary atherectomy system (CAS) was developed with a novel burr designed for a two-phase atherectomy procedure: low-speed drilling for lesion crossing and high-speed orbiting to achieve luminal gain, to removal the stenosis in artery. To investigate the CAS mechanism and validate its efficacy and safety. Engineering bench-top testings were conducted to evaluate the burr crossing time, luminal gain, debris size, temperature rise, and grinding force together with in-vivo and ex-vivo swine studies. The bench-top engineering testing results showed that the CAS can expand the calcified lumen diameter from 0.4 to 1.7 mm and the debris size, temperature rise, and grinding force were relatively low and safe. In the in-vivo swine study, the media and internal elastic membrane remained intact. The intima of the artery was removed at the 0-day follow-up and re-growthed at the 30-day follow-up. No abnormal phenomenon in the digital subtraction angiography, blood testing, ECG, and anatomy analysis were found. The ex-vivo study, by inserting a plaque surragate (graphite) into the coronary artery, showed similar efficacy in luminal gain and safety. This study demonstrated the efficacy and safety of CAS device with the novel two-phase burr design.
- Open Access
- 26 December 2024
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (2) , 457
Correction: AIM2 Deficiency Alleviates Cardiac Inflammation and Hypertrophy in HFD/STZ-Induced Diabetic Mice by Inhibiting the NLRC4/IRF1 Signaling Pathway
- 26 December 2024
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (2) , 457
Open AccessCorrection: AIM2 Deficiency Alleviates Cardiac Inflammation and Hypertrophy in HFD/STZ-Induced Diabetic Mice by Inhibiting the NLRC4/IRF1 Signaling Pathway
- 4 September 2024
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (1) , 94-109
AIM2 Deficiency Alleviates Cardiac Inflammation and Hypertrophy in HFD/STZ-Induced Diabetic Mice by Inhibiting the NLRC4/IRF1 Signaling Pathway
Absent in melanoma 2(AIM2) exacerbates atherosclerosis by inflammasome assembly. However, AIM2-mediated inflammation in diabetic cardiomyopathy remains inc
- 4 September 2024
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (1) , 94-109
AIM2 Deficiency Alleviates Cardiac Inflammation and Hypertrophy in HFD/STZ-Induced Diabetic Mice by Inhibiting the NLRC4/IRF1 Signaling Pathway
Absent in melanoma 2(AIM2) exacerbates atherosclerosis by inflammasome assembly. However, AIM2-mediated inflammation in diabetic cardiomyopathy remains inc
- Open Access
- 20 December 2016
- Published by MDPI AG in Marine Drugs
- Vol. 14 (12) , 231
Alginate Oligosaccharide Prevents Acute Doxorubicin Cardiotoxicity by Suppressing Oxidative Stress and Endoplasmic Reticulum-Mediated Apoptosis
Doxorubicin (DOX) is a highly potent chemotherapeutic agent, but its usage is limited by dose-dependent cardiotoxicity. DOX-induced cardiotoxicity involves increased oxidative stress and activated endoplasmic reticulum-mediated apoptosis. Alginate oligosaccharide (AOS) is a non-immunogenic, non-toxic and biodegradable polymer, with anti-oxidative, anti-inflammatory and anti-endoplasmic reticulum stress properties. The present study examined whether AOS pretreatment could protect against acute DOX cardiotoxicity, and the underlying mechanisms focused on oxidative stress and endoplasmic reticulum-mediated apoptosis. We found that AOS pretreatment markedly increased the survival rate of mice insulted with DOX, improved DOX-induced cardiac dysfunction and attenuated DOX-induced myocardial apoptosis. AOS pretreatment mitigated DOX-induced cardiac oxidative stress, as shown by the decreased expressions of gp91 (phox) and 4-hydroxynonenal (4-HNE). Moreover, AOS pretreatment significantly decreased the expression of Caspase-12, C/EBP homologous protein (CHOP) (markers for endoplasmic reticulum-mediated apoptosis) and Bax (a downstream molecule of CHOP), while up-regulating the expression of anti-apoptotic protein Bcl-2. Taken together, these findings identify AOS as a potent compound that prevents acute DOX cardiotoxicity, at least in part, by suppression of oxidative stress and endoplasmic reticulum-mediated apoptosis.
- 20 December 2016
- Published by MDPI AG in Marine Drugs
- Vol. 14 (12) , 231
Open AccessAlginate Oligosaccharide Prevents Acute Doxorubicin Cardiotoxicity by Suppressing Oxidative Stress and Endoplasmic Reticulum-Mediated Apoptosis
Doxorubicin (DOX) is a highly potent chemotherapeutic agent, but its usage is limited by dose-dependent cardiotoxicity. DOX-induced cardiotoxicity involves increased oxidative stress and activated endoplasmic reticulum-mediated apoptosis. Alginate oligosaccharide (AOS) is a non-immunogenic, non-toxic and biodegradable polymer, with anti-oxidative, anti-inflammatory and anti-endoplasmic reticulum stress properties. The present study examined whether AOS pretreatment could protect against acute DOX cardiotoxicity, and the underlying mechanisms focused on oxidative stress and endoplasmic reticulum-mediated apoptosis. We found that AOS pretreatment markedly increased the survival rate of mice insulted with DOX, improved DOX-induced cardiac dysfunction and attenuated DOX-induced myocardial apoptosis. AOS pretreatment mitigated DOX-induced cardiac oxidative stress, as shown by the decreased expressions of gp91 (phox) and 4-hydroxynonenal (4-HNE). Moreover, AOS pretreatment significantly decreased the expression of Caspase-12, C/EBP homologous protein (CHOP) (markers for endoplasmic reticulum-mediated apoptosis) and Bax (a downstream molecule of CHOP), while up-regulating the expression of anti-apoptotic protein Bcl-2. Taken together, these findings identify AOS as a potent compound that prevents acute DOX cardiotoxicity, at least in part, by suppression of oxidative stress and endoplasmic reticulum-mediated apoptosis.
- Open Access
- 28 October 2016
- Published by Springer Nature in Nutrition Journal
- Vol. 15 (1) , 1-10
Serum selenium level and gestational diabetes mellitus: a systematic review and meta-analysis
The association between serum selenium level and gestational diabetes mellitus (GDM) is controversial. The aim of our study was to systematically review available literature linking selenium to GDM for a comprehensive understanding of the relationship between serum selenium level and GDM in human. PubMed, The Cochrane Library and Medline were searched for studies published up to August 2016. Manual searches of references of the relevant original studies were carried out. Pooled estimates were measured using the fixed or random effect model. Overall effect was reported in a standard mean difference (SMD). All data were analyzed with Review Manager 5.3 and Stata 12.0. Of 44 references reviewed, seven studies involving 569 patients met our inclusion criteria and contributed to meta-analysis. All the studies were used to evaluate the relationship between serum selenium level and GDM. Selenium level was significantly lower in women with GDM than those without GDM (SMD = −1.17; 95 % CI: −1.98 to −0.35, P = 0.005). Subgroup analysis showed that such trend was consistent within the non-Caucasian population (Asia: SMD = −2.82; 95 % CI: −5.21 to −0.43, P = 0.02; Africa: SMD = −0.56; 95 % CI: −1.07 to −0.05, P = 0.03) and in the third trimester (SMD = −1.78; 95 % CI: −3.04 to −0.52, P = 0.006), but not within the Caucasian population (Europe: SMD = −0.6; 95 % CI: −1.98 to 0.78, P = 0.39) or in the second trimester (SMD = −0.68; 95 % CI: −1.6 to 0.25, P = 0.15). The available evidences suggested that serum selenium level was lower in women with GDM than those with normal glucose tolerance, especially within the non-Caucasian population and in the third trimester. However, well-designed prospective studies are needed to understand dynamic associations between selenium status and GDM risk.
- 28 October 2016
- Published by Springer Nature in Nutrition Journal
- Vol. 15 (1) , 1-10
Open AccessSerum selenium level and gestational diabetes mellitus: a systematic review and meta-analysis
The association between serum selenium level and gestational diabetes mellitus (GDM) is controversial. The aim of our study was to systematically review available literature linking selenium to GDM for a comprehensive understanding of the relationship between serum selenium level and GDM in human. PubMed, The Cochrane Library and Medline were searched for studies published up to August 2016. Manual searches of references of the relevant original studies were carried out. Pooled estimates were measured using the fixed or random effect model. Overall effect was reported in a standard mean difference (SMD). All data were analyzed with Review Manager 5.3 and Stata 12.0. Of 44 references reviewed, seven studies involving 569 patients met our inclusion criteria and contributed to meta-analysis. All the studies were used to evaluate the relationship between serum selenium level and GDM. Selenium level was significantly lower in women with GDM than those without GDM (SMD = −1.17; 95 % CI: −1.98 to −0.35, P = 0.005). Subgroup analysis showed that such trend was consistent within the non-Caucasian population (Asia: SMD = −2.82; 95 % CI: −5.21 to −0.43, P = 0.02; Africa: SMD = −0.56; 95 % CI: −1.07 to −0.05, P = 0.03) and in the third trimester (SMD = −1.78; 95 % CI: −3.04 to −0.52, P = 0.006), but not within the Caucasian population (Europe: SMD = −0.6; 95 % CI: −1.98 to 0.78, P = 0.39) or in the second trimester (SMD = −0.68; 95 % CI: −1.6 to 0.25, P = 0.15). The available evidences suggested that serum selenium level was lower in women with GDM than those with normal glucose tolerance, especially within the non-Caucasian population and in the third trimester. However, well-designed prospective studies are needed to understand dynamic associations between selenium status and GDM risk.
- 1 February 2016
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 91, 123-133
Exosomes derived from dendritic cells improve cardiac function via activation of CD4+ T lymphocytes after myocardial infarction
- 1 February 2016
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 91, 123-133
Exosomes derived from dendritic cells improve cardiac function via activation of CD4+ T lymphocytes after myocardial infarction